新诊断的多发性骨髓瘤（MM）患者的无进展生存期（PFS）和总生存期（OS）在临床试验中已经广泛发表，但来自实际世界环境的数据有限。我们确定了161例新诊断的MM患者的生存水平和预测结果的因素，这些患者的首线治疗在一家专门治疗这种B细胞恶性肿瘤的诊所开始。这些患者没有在初始治疗中接受自体干细胞移植，且高位基因风险患者所占比例较高（35%）。在中位随访42.7个月的情况下，该队列的中位PFS为22.8个月，中位OS为136.2个月。1、3和5年的生存率分别为97.5%、85.3%和76.2%。这些结果明显优于参加临床试验的患者和国家登记处的数据。年龄<65岁预示着更长的OS（p = 0.0004）。还评估了基线血清B细胞成熟抗原（sBCMA）水平，并显示中位数和平均数分别为320.3 ng/mL和551.1 ng/mL。此外，基线sBCMA水平在最低四分位数（≤136.2 ng/mL）的患者显示出较长的PFS（p = 0.0262）。这些结果为临床医生提供了一个关于在一家专门治疗MM患者的诊所开始治疗的未选择新诊断患者的生存情况的实际了解。© 2023. 作者/版权所有 排他许可 给 Springer Nature Switzerland AG。

Progression-free survival (PFS) and overall survival (OS) of newly diagnosed multiple myeloma (MM) patients have been widely published in the clinical trials setting, but data published from real-world settings are limited.We determined the survival and factors that predict outcomes among 161 unselected, newly diagnosed MM patients whose frontline therapy was started at a single clinic specializing in the treatment of this B-cell malignancy.None of these patients underwent an autologous stem cell transplantation as part of their initial therapy and the population had a high proportion (35%) of cytogenetic high-risk patients.With a median follow-up of 42.7 months, the cohort had a median PFS of 22.8 months and a median OS of 136.2 months. The 1-, 3-, and 5-year survival rates were 97.5%, 85.3%, and 76.2%, respectively. These results are considerably better than those reported from patients enrolled in clinical trials and those from countries with national registries. Age <65 years predicted for a longer OS (p = 0.0004). Baseline serum B-cell maturation antigen (sBCMA) levels were also assessed and showed median and mean levels of 320.3 ng/mL and 551.1 ng/mL, respectively. Furthermore, patients with baseline sBCMA levels in the lowest quartile (≤136.2 ng/mL) showed a longer PFS (p = 0.0262).These results provide clinicians with a real-world understanding of the survival of unselected, newly diagnosed patients initiating therapy in a clinic specializing in the care of MM patients.© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.